Bibliography
1. Botosso VF, Jorge SAC, Astray RM, Guimaraes AMS, Mathor MB, Carneiro PS, Durigon EL, Covas D, Oliveira DBL, Oliveira RN, Maria DA, Eto SF, Gallina NMF, Pidde G, Squaiella-Baptistão CS, Silva DT, Villas-Boas IM, Fernandes DC, Auada AVV, Banari AC, Filho AFS, Bianconi C, Utescher CLA, Oliveira DCA, Mariano DOC, Barbosa FF, Rondon G, Kapronezai J, Silva J G, Goldfeder MB, Comone P, Junior REC, Pereira TTS, Wen FH, Tambourgi DV, Chudzinski-Tavassi AM (2022) Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19. Sci Rep 12: 3890.
2. De Vito A, Colpani A, Saderi L, Puci M, Zauli B, Fiore V, Fois M, Meloni MC, Bitti A, Di Castri C, Maida I, Babudieri S, Sotgiu G, Madeddu G. (2022) Impact of early SARS-CoV-2 antiviral therapy on disease progression. Viruses 15: 71.
3. Dong W, Mead H, Tian L, Park JG, Garcia JI, Jaramillo S, Barr T, Kollath DS, Coyne VK, Stone NE, Jones A, Zhang J, Li A, Wang LS, Milanes-Yearsley M, Torrelles JB, Martinez-Sobrido L, Keim PS, Barker BM, Caligiuri MA, Yu J (2022) The K18-Human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol: e0096421.
4. Golden JW, Cline CR, Zeng X, Garrison AR, Carey BD, Mucker EM, White LE, Shamblin JD, Brocato RL, Liu J, Babka AM, Rauch HB, Smith JM, Hollidge BS, Fitzpatrick C, Badger CV, Hooper JW (2020) Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight 5: e142032.
5. Jha A, Barker D, Lew J, Manoharan V, Kessel JV, Haupt R, Toth D, Frieman M, Falzarano D, Kodihalli S (2022) Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. Sci Rep 12: 16956.
6. León G, Herrera M, Vargas M, Arguedas M, Sánchez A, Segura A, Gómez A, Solano G, Aguilar E C, Risner K, Narayanan A, Bailey C, Villalta M, Hernández A, Sánchez A, Cordero D, Solano D, Durán G, Segura E, Cerdas M, Umaña D, Moscoso E, Estrada R, Gu-tiérrez J, Méndez M, Castillo AC, Sánchez L, Sánchez R, Gutiérrez JM, Díaz C, Alape A (2021) Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19. Sci Rep 11: 9825.
7. Li E, Han Q, Bi J, Wei S, Wang S, Zhang Y, Liu J, Feng N, Wang T, Wu J, Yang S, Zhao Y, Liu B, Yan F, Xia X (2023) Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. Front Immunol 14: 1066730.
8. Luis Eduardo Cunha, Stolet AA, Strauch MA, Pereira VAR, Dumard CH, Gomes AMO, Souza PNC, Fonseca JG, Pontes FE, Meirelles LGR, Albuquerque JWM, Sacramento CQ, Rodrigues NF, Lima TM, Alvim RGF, Marsili FF, Caldeira MM, Higa LM, Monteiro FL, Zingali RB, Oliveira GAP, Souza TML, Tanuri A, Oliveira AC, Guedes H L M, Castilho L R , Silva J L (2020) Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapy. Cold Spring Harbor Laboratory, bioRxiv 17: 254375
9. Maccio U, Zinkernagel AS, Shambat SM, Zeng X, Cathomas G, Ruschitzka F, Schuepbach RA, Moch H, Varga Z. SARS-CoV-2 (2021) Leads to a small vessel endotheliitis in the heart. EBioMedicine 63: 103182.
10. Moreira-Soto A, Arguedas M, Brenes H, Buján W, Corrales-Aguilar E, Díaz C, Echeverri A, Flores-Díaz M, Gómez A, Hernández A, Herrera M, León G, Macaya R, Kühne A, Molina-Mora JA, Mora J, Sanabria A, Sánchez A, Sánchez L, Segura Á, Segura E, Solano D, Soto C, Stynoski JL, Vargas M, Villalta M, Reusken CBEM, Drosten C, Gutiérrez JM, Alape-Girón A, Drexler JF (2021) High efficacy of therapeutic equine hyperimmune antibodies against SARS-CoV-2 variants of concern. Frontiers in Medicine. 8: 735853.
11. Onen EA, Sonmez K, Yildirim F, Demirci EK, Gurel A (2022) Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of Covid-19 disease. All Life 15: 771-793.
12. Pan X, Zhou P, Fan T, Wu Y, Zhang J, Shi X, Shang W, Fang L, Jiang X, Shi J, Sun Y, Zhao S, Gong R, Chen Z, Xiao G (2020) Im-munoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res 182: 104868.
13. Schoell A, Heyde B, Weir D, Po-Chang C, Yiding H, Tung D (2009) Euthanasia method for mice in rapid time-course pulmonary. Pharmacokinetic Studies 48: 506.
14. Suvarna KS, Layton C, Bancroft JD (2018) Bancroft’s theory and practice of histological techniques E-Book. Elsevier health sciences, Philadelphia, pp 286-291.
15. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang L, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS (2020) SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol 21: 1327-1335.
16. Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G (2020) SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res 21: 182.
17. Yu P, Deng W, Bao L, Qu Y, Xu Y, Zhao W, Han Y, Qin C (2022) Comparative pathology of the nasal epithelium in K18-hACE2 Tg mice, hACE2 Tg mice, and hamsters infected with SARS-CoV-2. Vet Pathol 59: 602-612.
18. Zhang Q, Wang Y, Qi C, Shen L, Li J (2020) Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol 92: 540-545.
Go to article
en
pl
